Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL29634285

CC(C)(C)NS(=O)(=O)c1ccccc1.O=C(O)C(F)(F)F

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
KMT2A Q03164 4/20 0.53
MEN1 O00255 3/20 0.53
LMNA P02545 2/20 0.53
KDM4E B2RXH2 1/20 0.53
NPC1 O15118 1/20 0.53
HPGD P15428 1/20 0.53
RAB9A P51151 1/20 0.53
GAA P10253 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ALDH1A1 P00352 3/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2C9 P11712 2/20 0.47
MAPK1 P28482 1/20 0.47
PARG Q86W56 1/20 0.47
HTT P42858 3/20 0.47
CYP2D6 P10635 1/20 0.47
PKM P14618 1/20 0.47
CNR1 P21554 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL349527 0.87 MAPT (0.66) MAPTSMN1; SMN2KMT2AMEN1LMNA
Trifluoroacetic Acid SCHEMBL15918326 0.86 GAA (0.56) MAPTSMN1; SMN2KMT2AMEN1HPGD
Boric Acid SCHEMBL5885888 0.84 MAPT (0.58) MAPTSMN1; SMN2KMT2AMEN1LMNA
SCHEMBL4680184 0.84 MAPT (0.58) MAPTSMN1; SMN2KMT2AMEN1LMNA
Trifluoroacetic Acid SCHEMBL2224180 0.82 NR3C2 (0.54) SMN1; SMN2KMT2ALMNANPC1HPGD
Trifluoroacetic Acid SCHEMBL1805155 0.82 NR3C2 (0.54) SMN1; SMN2KMT2ALMNANPC1HPGD
Trifluoroacetic Acid SCHEMBL27626580 0.80 CA1 (0.50) SMN1; SMN2KMT2AMEN1HPGDGAA
SCHEMBL10402270 0.80 BCAT1 (0.50) MAPTSMN1; SMN2KMT2AMEN1LMNA
Trifluoroacetic Acid SCHEMBL28039127 0.79 NR3C2 (0.51) SMN1; SMN2KMT2AMEN1LMNANPC1
Trifluoroacetic Acid SCHEMBL18429767 0.79 CYP2C19 (0.59) SMN1; SMN2KMT2AMEN1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108350062-B Targeted protein degradation to attenuate adverse inflammatory responses associated with adoptive T cell therapy 达纳-法伯癌症研究所股份有限公司 2022-10-14 CN disclosed
US-20220135967-A1 TUNABLE ENDOGENOUS PROTEIN DEGRADATION DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220135967-A1 TUNABLE ENDOGENOUS PROTEIN DEGRADATION PSMG3, MYCBP, DBN1 MAPT 3101/4885SMN1; SMN2 4262/4885KMT2A 2488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.